Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02422940 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
A Phase 3 study, sponsored by Acorda Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 294
- Enrollment target
NCT02422940 is a Phase 3 study that was terminated before completion, run by Acorda Therapeutics. The registered enrollment target is 294 participants.
The verdict
NCT02422940, a Phase 3 study, was terminated before completion, sponsored by Acorda Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 294 participants
- Enrollment target
Study Summary
This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.
Interventions
- DRUG dalfampridine-ER 7.5 mg
- DRUG dalfampridine-ER 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02422940
The ClinicalTrials.gov registry entry for NCT02422940 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dalfampridine-ER 7.5 mg is the first listed.
NCT02422940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02422940 about?
NCT02422940 is a clinical study titled "Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.". This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.
What is the current status of trial NCT02422940?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 294 participants. The study started on 2015-04. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02422940?
The interventions under investigation include: dalfampridine-ER 7.5 mg (DRUG), dalfampridine-ER 10 mg (DRUG).
Who is sponsoring clinical trial NCT02422940?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.